Arvinas CSO granted stock options and RSUs

Cacace Angela M reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cacace Angela M reported acquisition or exercise transactions in this Form 4 filing.

ARVINAS, INC. reported that Chief Scientific Officer Angela M. Cacace received new equity awards on February 26, 2026. She was granted options to purchase 67,000 shares of common stock and 45,000 restricted stock units, each RSU representing one share upon settlement for no cash payment.

The RSUs vest in four equal annual installments on February 26 of 2027, 2028, 2029 and 2030, contingent on continued service. The stock options also vest over four years, with 25% vesting on February 26, 2027 and the remaining shares vesting in equal monthly installments through February 26, 2030, subject to ongoing employment.

Insider Trade Summary

Grant/Award: 112,000 shares

Grant/Award 2 txns

Insider Cacace Angela M

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	67,000	$0.00	$0.00
Grant/Award	Common Stock	45,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 67,000 contracts (Direct); Common Stock — 192,623 shares (Direct)

Footnotes (2)

F1. The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2. The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ARVN disclose for Angela Cacace?

ARVINAS, INC. disclosed that Chief Scientific Officer Angela M. Cacace received equity awards on February 26, 2026, including stock options and restricted stock units. These grants are part of the company’s 2018 Stock Incentive Plan and vest over a four-year period, subject to continued service.

How many stock options were granted to ARVN’s Chief Scientific Officer?

Angela M. Cacace was granted stock options covering 67,000 shares of ARVINAS, INC. common stock. These options vest over four years, with 25% vesting on February 26, 2027 and the remainder vesting in equal monthly installments through February 26, 2030, contingent on continued service.

How many restricted stock units did Angela Cacace receive from ARVN?

Angela M. Cacace received 45,000 restricted stock units from ARVINAS, INC. Each RSU represents one share of common stock upon settlement at no cash cost. The RSUs vest in four equal annual installments on February 26, 2027, 2028, 2029 and 2030, subject to continued employment.

Are Angela Cacace’s ARVN equity awards open-market purchases or grants?

The ARVINAS, INC. filing shows these are grants, not open-market purchases. Both the 67,000 stock options and 45,000 restricted stock units were awarded under the 2018 Stock Incentive Plan at no purchase price, with vesting tied to her continued service over four years.

What conditions affect vesting of Angela Cacace’s ARVN RSUs and options?

Vesting of Angela M. Cacace’s ARVINAS, INC. RSUs and options depends on her continued service. RSUs vest in four annual tranches from February 26, 2027 to February 26, 2030. Options vest 25% on February 26, 2027, with remaining shares vesting monthly through February 26, 2030.

Under which plan were the new ARVN equity awards granted?

The equity awards to Angela M. Cacace were granted under ARVINAS, INC.’s 2018 Stock Incentive Plan. This plan allows the company to issue stock options and restricted stock units to employees, with vesting schedules and service conditions specified in each individual award agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/02/2026 - 09:00 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cacace Angela M

(Last)

(First)

(Middle)

C/O ARVINAS, INC.

5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)

NEW HAVEN

06511

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		45,000⁽¹⁾	A	$0	192,623	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$13.38	02/26/2026		A		67,000		⁽²⁾	02/25/2036	Common Stock	67,000	$0	67,000	D

Explanation of Responses:

1. The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

2. The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date.

Remarks:

	/s/ Jared Freedberg, as attorney-in-fact for Angela M. Cacace	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR